EPCA-2
The common choices for screening prostate cancer are the digital rectal exam and the prostate specific antigen (PSA) blood test. Last year, another method of screening prostate cancer has been tested. It’s called the early prostate cancer antigen 2 or EPCA-2. It is another method of blood testing and said to be able to determine the spreading of the cancer and said to be better than PSA with regard to this aspect.
According to Robert H. Getzenberg, PhD, director of urology research at Johns Hopkins University’s Brady Urological Institute the test has 3% margin of error. This means that if the test shows that the patient has prostate cancer, it is 97% accurate. Once this method is approved, it is expected that this will replace other existing tests and shall be widely used.



MRI’s have long been used as a diagnostic tool for cancer and the many diseases that plague us. Newer generations of MRI scanners are allowing better scans that tracks treatment success of failure and is now also capable of detecting early signs of the deadly disease that more often goes unnoticed before serious symptoms prompts treatment. Cancer as well all know seldom manifests early signs, abnormalities being known only during later stages of the disease when it has already progressed to a non-treatable stage. Effective use of MRI scans to diagnose, detect and monitor the progression of treatment allowing better views of the deadly disease that is
Men who have high consumption of green tea, long known for its cancer fighting components have shown quite a significant reduction of cancer causing markers according to research. This gives credence to the cancer fighting abilities of Green Tea of which are much hyped phytochemicals. These compounds have long been regarded as
Scientists from the Wayne State University have identified a form of the gene gaectin-3 to be a good indicator of the progression of prostate cancer in patients. Lack of the
Metastatic Prostate Cancer is known to be the main cause of death due to
Studies are under way to use the cancer cell’s own genes to emphasize the ones that tells it to self-destruct known as Fatty Acid Synthase (FASN). The enzyme is a key to understanding the growth cycle of the